HOME >> BIOLOGY >> NEWS
Promising antiobesity drug fails to produce clinically meaningful weight loss

A drug designed to target a powerful hunger-stimulating factor that has long been considered a prime target for antiobesity therapy failed to produce clinically meaningful weight loss in obese people in a long-term clinical trial. People taking the drug known as MK-0557 for a year consistently lost about three pounds more than those taking a placebo, researchers reported in the October issue of the journal Cell Metabolism, published by Cell Press.

The results, which are the culmination of a 10 year program of study, suggest MK-0557 alone will not provide a useful weapon in the fight against obesity. The possibility remains, however, that the treatment could potentially play a role in future combination therapies, according to the research team that includes Steven Heymsfield and Ngozi Erondu of Merck & Co., Inc. Heymsfield said that combination therapies were among the possibilities being considered by scientists conducting obesity research.

"The current findings add to a growing sense that you will have to try a lot of different targets or get an even better understanding of the scientific underpinnings in order to unwire the food intake system with some combination of drugs," Heymsfield said. "Finding safe and effective antiobesity drugs is not unlike the challenge and complexity of sending the space shuttle into orbit."

MK-0557 blocks brain receptors that respond to the hunger factor called neuropeptide Y (NPY). NPY, whose role in driving appetite Heymsfield likens to an accelerator in a car, is one in a chain of players in the hunger pathway that includes the fat hormone leptin. Leptin hormone sends signals to the brain about the level of energy stores available, information that is then used to gauge metabolism and appetite.

Scientists discovered NPY more than two decades ago, making it one of the first identified appetite stimulants, but it was only after the discovery of leptin in 1994 that the neuropeptide's key role an
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
3-Oct-2006


Page: 1 2 3

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising preclinical results with live attenuated H5N1 vaccines
4. Promising new research on hereditary diseases
5. Promising cell protein may play role in infection and dry eye
6. Promising anti-TB compound finally can be synthesized with ease
7. Promising results in the battle against incurable ALS muscle disease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Weight control protein may yield antiobesity drugs
10. Study fails to verify gene variations as risk factors for certain cardiovascular problems
11. Moral judgment fails without feelings

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/12/2019)... ... November 12, 2019 , ... ... from nonprofit U.S. universities and research institutions for its Instrumentation Grant for ... up to $1.2 million per site for the acquisition of instrumentation, development and ...
(Date:11/9/2019)... ... November 08, 2019 , ... StageBio ... histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device ... Histo-Scientific Research Laboratories (HSRL), Vet Path Services (VPS) and Tox Path Specialists ...
(Date:11/6/2019)... ... November 06, 2019 , ... Genomenon® ... Engine now includes the ability to search the entirety of the genomic literature ... genetic and rare diseases. , Patients, particularly those with rare diseases, don’t always ...
Breaking Biology News(10 mins):
(Date:10/15/2019)... ... ... ARPR , an award-winning tech PR agency at the epicenter of the future of ... of the Year in the Ragan’s Health Care PR & Marketing Awards. This award marks ... also revealed today that its healthIT practice group grew by 18 percent in Q3 this ...
(Date:10/10/2019)... ... October 09, 2019 , ... As World ... middle school and high school students have improved neuro-cognitive executive skills to enhance ... physical fitness, and apply lifelong social/interpersonal, leadership, problem-solving and coping skills, due to ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... of clinical research centers in Europe. All Pratia research centers have completed VirTrial’s ... become trained and certified as Virtual Trial Capable and prepared to conduct decentralized ...
(Date:10/8/2019)... MELBOURNE, Fla. (PRWEB) , ... October 07, 2019 ... ... and development of low level laser therapy technology (“3LT®”), today announces that the ... to market its EVRL low level laser for the temporary relief of chronic ...
Breaking Biology Technology:
Cached News: